{
    "hands_on_practices": [
        {
            "introduction": "Post-translational modifications often exert their effects by altering a protein's fundamental physicochemical properties. This practice explores one of the most important examples: the neutralization of charge by lysine acetylation. By applying principles of acid-base chemistry, you will calculate the change in a protein's net charge and understand how this directly impacts its interaction with other biomolecules, such as the negatively charged DNA backbone in chromatin .",
            "id": "5075864",
            "problem": "A chromatin-associated protein is studied to understand how post-translational modification (PTM) alters its electrostatic properties relevant to gene regulation. At physiological $\\mathrm{pH}$ of $7.4$, the $\\varepsilon$-amino group of lysine side chains is a basic site that can carry a positive charge when protonated. Consider a scenario in which $n$ lysine residues are enzymatically acetylated, converting their $\\varepsilon$-amino groups to neutral amides under physiological conditions. Assume the following:\n- The net charge $Q$ of the protein is defined by the sum of the charges of its ionizable groups, $Q = \\sum_{i} q_{i}$.\n- Before acetylation, each lysine side chain has an acid dissociation constant $\\mathrm{p}K_{a} = 10.5$ in the protein environment, and after acetylation it contributes $0$ to the net charge over the relevant $\\mathrm{pH}$ range.\n- The fraction of lysine side chains that are protonated (and thus positively charged) at a given $\\mathrm{pH}$ can be determined from acid–base equilibrium.\n- Other ionizable residues and microenvironmental shifts in $\\mathrm{p}K_{a}$ can be neglected for this calculation, and the charges of individual groups are independent and additive.\n\nStarting from core acid–base and charge definitions applicable to biomolecules, derive an expression for the change in net charge $\\Delta Q$ of the protein due solely to acetylation of $n$ lysine residues at $\\mathrm{pH} = 7.4$. Then, briefly explain mechanistically how the resulting change in electrostatics would be expected to influence protein–DNA interactions in chromatin. Provide your final $\\Delta Q$ as a single closed-form analytic expression. No rounding is required.",
            "solution": "The problem is first validated to ensure it is scientifically grounded, well-posed, and objective.\n\n**Step 1: Extract Givens**\n- The context is a chromatin-associated protein.\n- The process is the enzymatic acetylation of $n$ lysine residues.\n- Physiological $\\mathrm{pH} = 7.4$.\n- The acetylated group is the $\\varepsilon$-amino group of lysine.\n- The net charge of the protein is $Q = \\sum_{i} q_{i}$.\n- Before acetylation, the acid dissociation constant of the lysine side-chain amino group is $\\mathrm{p}K_{a} = 10.5$.\n- After acetylation, the modified residue's charge contribution is $0$.\n- Assumptions: The fraction of protonated residues obeys acid–base equilibrium; contributions from other ionizable residues are neglected; charges are independent and additive.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem statement is scientifically sound. It describes lysine acetylation, a fundamental post-translational modification in molecular biology, particularly in the context of histone proteins and chromatin regulation. The use of the Henderson-Hasselbalch equation to determine the protonation state of an ionizable group is a standard and correct application of acid-base chemistry principles. The given values for physiological $\\mathrm{pH}$ ($7.4$) and the approximate $\\mathrm{p}K_{a}$ of a lysine side chain ($10.5$) are standard in biochemistry. The problem is well-posed, self-contained, and provides all necessary information and simplifying assumptions to derive a unique, meaningful solution. The language is objective and free of ambiguity. No violations of the validation criteria are identified.\n\n**Step 3: Verdict and Action**\nThe problem is deemed **valid**. The derivation of a solution will now proceed.\n\n**Derivation of the Change in Net Charge, $\\Delta Q$**\n\nThe change in the net charge of the protein, $\\Delta Q$, is the difference between its final charge ($Q_{\\text{final}}$) and its initial charge ($Q_{\\text{initial}}$).\n$$ \\Delta Q = Q_{\\text{final}} - Q_{\\text{initial}} $$\nGiven the assumption that we only consider the $n$ lysine residues being modified, this change is $n$ times the average change in charge for a single lysine residue, $\\Delta q_{\\text{lys}}$.\n$$ \\Delta Q = n \\cdot \\Delta q_{\\text{lys}} = n \\cdot (\\langle q_{\\text{after}} \\rangle - \\langle q_{\\text{before}} \\rangle) $$\nHere, $\\langle q_{\\text{before}} \\rangle$ is the average charge of a single lysine side chain before acetylation, and $\\langle q_{\\text{after}} \\rangle$ is its average charge after acetylation.\n\nFirst, we determine $\\langle q_{\\text{after}} \\rangle$. The problem states that after acetylation, the side chain is a neutral amide, contributing $0$ to the net charge.\n$$ \\langle q_{\\text{after}} \\rangle = 0 $$\n\nNext, we determine $\\langle q_{\\text{before}} \\rangle$. Before acetylation, the lysine $\\varepsilon$-amino group is a basic site involved in the following acid-base equilibrium:\n$$ \\text{Lys-NH}_3^+ \\rightleftharpoons \\text{Lys-NH}_2 + \\text{H}^+ $$\nThe protonated form ($\\text{Lys-NH}_3^+$) has a charge of $+1$, and the deprotonated form ($\\text{Lys-NH}_2$) has a charge of $0$. The average charge of the residue, $\\langle q_{\\text{before}} \\rangle$, is equal to the mole fraction of the protonated, positively charged form, which we denote as $f_{\\text{prot}}$.\n$$ \\langle q_{\\text{before}} \\rangle = (+1) \\cdot f_{\\text{prot}} + (0) \\cdot (1 - f_{\\text{prot}}) = f_{\\text{prot}} $$\nThe fraction $f_{\\text{prot}}$ is given by:\n$$ f_{\\text{prot}} = \\frac{[\\text{Lys-NH}_3^+]}{[\\text{Lys-NH}_3^+] + [\\text{Lys-NH}_2]} $$\nTo find this fraction, we use the Henderson-Hasselbalch equation, which relates $\\mathrm{pH}$, $\\mathrm{p}K_a$, and the concentrations of the conjugate acid and base:\n$$ \\mathrm{pH} = \\mathrm{p}K_a + \\log_{10} \\left( \\frac{[\\text{Lys-NH}_2]}{[\\text{Lys-NH}_3^+]} \\right) $$\nRearranging to solve for the ratio of concentrations:\n$$ \\mathrm{pH} - \\mathrm{p}K_a = \\log_{10} \\left( \\frac{[\\text{Lys-NH}_2]}{[\\text{Lys-NH}_3^+]} \\right) $$\n$$ 10^{\\mathrm{pH} - \\mathrm{p}K_a} = \\frac{[\\text{Lys-NH}_2]}{[\\text{Lys-NH}_3^+]} $$\nNow, we substitute this ratio back into the expression for $f_{\\text{prot}}$. By dividing the numerator and denominator by $[\\text{Lys-NH}_3^+]$, we get:\n$$ f_{\\text{prot}} = \\frac{1}{1 + \\frac{[\\text{Lys-NH}_2]}{[\\text{Lys-NH}_3^+]}} $$\nSubstituting the expression from the Henderson-Hasselbalch equation:\n$$ f_{\\text{prot}} = \\frac{1}{1 + 10^{\\mathrm{pH} - \\mathrm{p}K_a}} $$\nSo, the average charge of a single lysine residue before acetylation is:\n$$ \\langle q_{\\text{before}} \\rangle = \\frac{1}{1 + 10^{\\mathrm{pH} - \\mathrm{p}K_a}} $$\nNow we can calculate the total change in charge, $\\Delta Q$, for the acetylation of $n$ such residues.\n$$ \\Delta Q = n \\cdot (\\langle q_{\\text{after}} \\rangle - \\langle q_{\\text{before}} \\rangle) = n \\left( 0 - \\frac{1}{1 + 10^{\\mathrm{pH} - \\mathrm{p}K_a}} \\right) $$\n$$ \\Delta Q = - \\frac{n}{1 + 10^{\\mathrm{pH} - \\mathrm{p}K_a}} $$\nSubstituting the given values, $\\mathrm{pH} = 7.4$ and $\\mathrm{p}K_{a} = 10.5$:\n$$ \\Delta Q = - \\frac{n}{1 + 10^{7.4 - 10.5}} $$\n$$ \\Delta Q = - \\frac{n}{1 + 10^{-3.1}} $$\nThis expression represents the total decrease in the protein's net charge, in units of elementary charge, due to the acetylation of $n$ lysine residues. Since $\\mathrm{pH} < \\mathrm{p}K_a$, the exponent is negative, the denominator is close to $1$, and the charge of each lysine residue is close to $+1$ before modification. The change in charge is therefore negative and close to $-n$, as expected.\n\n**Mechanistic Explanation of Influence on Protein–DNA Interactions**\n\nThe derived negative change in charge, $\\Delta Q < 0$, signifies a reduction in the net positive charge of the chromatin-associated protein. In the context of chromatin, proteins such as histones are rich in basic residues like lysine and arginine, giving their histone tail domains a significant net positive charge at physiological $\\mathrm{pH}$. This positive charge promotes strong electrostatic attraction to the negatively charged phosphodiester backbone of DNA. This attraction is a key force in compacting DNA into a condensed, heterochromatin-like state, which is generally transcriptionally silent.\n\nThe acetylation of $n$ lysine residues neutralizes $n$ positive charges, thereby reducing the protein's overall positive charge. This weakens the electrostatic affinity between the protein and the DNA backbone. As a result, the chromatin structure becomes less condensed and more \"open\" or \"relaxed\" (euchromatin-like). This decondensation increases the accessibility of the DNA to the transcriptional machinery, including transcription factors and RNA polymerase. Consequently, lysine acetylation is a canonical mark of transcriptionally active or poised genes, as it facilitates the process of gene expression by remodeling the local chromatin environment.",
            "answer": "$$ \\boxed{-\\frac{n}{1 + 10^{-3.1}}} $$"
        },
        {
            "introduction": "Beyond altering properties, PTMs are critical for regulating a protein's lifespan in the cell. This exercise focuses on the Ubiquitin-Proteasome System, where PTMs act as signals for degradation. You will use a first-order kinetic model to see how a mutation affecting a degradation signal (a degron) changes a protein's half-life, altering its steady-state abundance and leading to significant phenotypic consequences .",
            "id": "5075871",
            "problem": "A dosage-sensitive transcription factor that controls cell-cycle entry is matured in the endoplasmic reticulum and turned over predominantly by the Ubiquitin-Proteasome System (UPS). Recognition for ubiquitination depends on a C-terminal degron that is bound by a specific E3 ubiquitin ligase (E3). In wild-type cells, a pulse–chase experiment determines a first-order degradation rate constant $k_{\\deg}$ of $0.12~\\mathrm{h}^{-1}$ for this transcription factor. A patient presents with a missense variant in the degron that reduces E3 binding occupancy by $60$ percent relative to wild type, and in this system the effective $k_{\\deg}$ scales linearly with E3 occupancy. Assume that synthesis (translation) and all other maturation steps remain unchanged, and that protein decay follows first-order kinetics governed by the ordinary differential equation $\\frac{dP}{dt}=-k_{\\deg}P$, where $P(t)$ is the protein abundance at time $t$.\n\nStarting from the first-order decay law, derive the general expression for the protein half-life $t_{1/2}$ in terms of $k_{\\deg}$, then, using the given data, compute the mutant half-life. Round your numerical result to three significant figures. Express the half-life in hours. Finally, justify qualitatively the expected phenotypic consequences of this degron-disrupting mutation for a dosage-sensitive cell-cycle transcription factor at steady state, based on the relationship between synthesis and degradation.\n\nYour final numeric answer should be only the mutant half-life.",
            "solution": "The problem statement is first subjected to validation.\n\n### Step 1: Extract Givens\n- A dosage-sensitive transcription factor that controls cell-cycle entry.\n- Protein maturation occurs in the endoplasmic reticulum.\n- Protein turnover is predominantly via the Ubiquitin-Proteasome System (UPS).\n- Recognition for ubiquitination depends on a C-terminal degron.\n- The degron is bound by a specific E3 ubiquitin ligase (E3).\n- Wild-type first-order degradation rate constant: $k_{\\deg} = 0.12~\\mathrm{h}^{-1}$.\n- A patient has a missense variant in the degron.\n- The variant reduces E3 binding occupancy by $60$ percent relative to wild type.\n- The effective $k_{\\deg}$ scales linearly with E3 occupancy.\n- Synthesis (translation) and all other maturation steps remain unchanged.\n- Protein decay follows first-order kinetics: $\\frac{dP}{dt}=-k_{\\deg}P$.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is scientifically grounded, well-posed, and objective.\n- **Scientific and Factual Soundness:** The problem statement is based on established principles of molecular cell biology and medical genetics. The roles of the endoplasmic reticulum, the Ubiquitin-Proteasome System (UPS), E3 ligases, and degrons in protein maturation and turnover are fundamental concepts. The idea that a missense mutation can affect protein-protein interactions (such as E3-degron binding) and subsequently alter protein stability is a common mechanism in genetic disease. First-order kinetics is a standard and appropriate model for the decay of many proteins.\n- **Well-Posedness:** The problem is self-contained. It provides all necessary data ($k_{\\deg}$ for wild-type, percentage reduction in binding, the scaling relationship between binding and $k_{\\deg}$) and a clear mathematical model ($\\frac{dP}{dt}=-k_{\\deg}P$) to derive a unique solution for the mutant protein's half-life.\n- **Objectivity:** The problem uses precise, quantitative language (e.g., \"$60$ percent\", \"scales linearly\") and avoids any subjective or ambiguous terminology.\n\n### Step 3: Verdict and Action\nThe problem is deemed **valid**. A full solution will be provided.\n\n***\n\nThe solution involves three parts as requested: deriving the general expression for half-life, computing the mutant half-life, and providing a qualitative justification for the phenotypic consequences.\n\n**Part 1: Derivation of the general expression for protein half-life ($t_{1/2}$)**\n\nThe decay of the protein is described by the first-order ordinary differential equation:\n$$ \\frac{dP}{dt} = -k_{\\deg}P $$\nwhere $P(t)$ is the protein abundance at time $t$ and $k_{\\deg}$ is the degradation rate constant. This is a separable differential equation. We separate the variables $P$ and $t$:\n$$ \\frac{dP}{P} = -k_{\\deg} dt $$\nWe integrate both sides of the equation. Let the initial protein abundance at $t=0$ be $P(0) = P_0$. We integrate from $t=0$ to a general time $t$:\n$$ \\int_{P_0}^{P(t)} \\frac{1}{P'} dP' = \\int_{0}^{t} -k_{\\deg} dt' $$\nPerforming the integration yields:\n$$ [\\ln(P')]_{P_0}^{P(t)} = [-k_{\\deg}t']_{0}^{t} $$\n$$ \\ln(P(t)) - \\ln(P_0) = -k_{\\deg}t $$\nUsing the properties of logarithms, we can write:\n$$ \\ln\\left(\\frac{P(t)}{P_0}\\right) = -k_{\\deg}t $$\nTo solve for $P(t)$, we exponentiate both sides:\n$$ \\frac{P(t)}{P_0} = \\exp(-k_{\\deg}t) $$\n$$ P(t) = P_0 \\exp(-k_{\\deg}t) $$\nThe half-life, $t_{1/2}$, is defined as the time required for the protein abundance to decrease to half of its initial value, i.e., $P(t_{1/2}) = \\frac{P_0}{2}$. Substituting this into the equation for $P(t)$:\n$$ \\frac{P_0}{2} = P_0 \\exp(-k_{\\deg}t_{1/2}) $$\nDividing by $P_0$ (which is non-zero):\n$$ \\frac{1}{2} = \\exp(-k_{\\deg}t_{1/2}) $$\nTo solve for $t_{1/2}$, we take the natural logarithm of both sides:\n$$ \\ln\\left(\\frac{1}{2}\\right) = -k_{\\deg}t_{1/2} $$\nSince $\\ln(1/2) = -\\ln(2)$, the equation becomes:\n$$ -\\ln(2) = -k_{\\deg}t_{1/2} $$\nTherefore, the general expression for the half-life is:\n$$ t_{1/2} = \\frac{\\ln(2)}{k_{\\deg}} $$\n\n**Part 2: Computation of the mutant half-life**\n\nFirst, we must determine the degradation rate constant for the mutant protein, $k_{\\deg, \\text{mutant}}$.\nThe wild-type degradation rate constant is given as $k_{\\deg, \\text{WT}} = 0.12~\\mathrm{h}^{-1}$.\nLet the E3 ligase binding occupancy for the wild-type protein be $O_{\\text{WT}}$. The mutant protein exhibits a $60\\%$ reduction in E3 binding occupancy relative to the wild type. This means the occupancy of the mutant, $O_{\\text{mutant}}$, is:\n$$ O_{\\text{mutant}} = O_{\\text{WT}} - 0.60 \\times O_{\\text{WT}} = (1 - 0.60) O_{\\text{WT}} = 0.40 \\times O_{\\text{WT}} $$\nThe problem states that the effective degradation rate constant, $k_{\\deg}$, scales linearly with E3 occupancy, $O$. This can be expressed as $k_{\\deg} = c \\times O$, where $c$ is a constant of proportionality.\nFor the wild-type and mutant proteins, we have:\n$$ k_{\\deg, \\text{WT}} = c \\times O_{\\text{WT}} $$\n$$ k_{\\deg, \\text{mutant}} = c \\times O_{\\text{mutant}} $$\nWe can find the ratio of the rate constants:\n$$ \\frac{k_{\\deg, \\text{mutant}}}{k_{\\deg, \\text{WT}}} = \\frac{c \\times O_{\\text{mutant}}}{c \\times O_{\\text{WT}}} = \\frac{O_{\\text{mutant}}}{O_{\\text{WT}}} = 0.40 $$\nTherefore, the mutant degradation rate constant is $40\\%$ of the wild-type rate constant:\n$$ k_{\\deg, \\text{mutant}} = 0.40 \\times k_{\\deg, \\text{WT}} = 0.40 \\times 0.12~\\mathrm{h}^{-1} = 0.048~\\mathrm{h}^{-1} $$\nNow, we use the half-life formula derived in Part 1 to compute the mutant half-life, $t_{1/2, \\text{mutant}}$:\n$$ t_{1/2, \\text{mutant}} = \\frac{\\ln(2)}{k_{\\deg, \\text{mutant}}} = \\frac{\\ln(2)}{0.048~\\mathrm{h}^{-1}} $$\nUsing the value $\\ln(2) \\approx 0.693147$:\n$$ t_{1/2, \\text{mutant}} \\approx \\frac{0.693147}{0.048}~\\mathrm{h} \\approx 14.44056~\\mathrm{h} $$\nRounding to three significant figures as requested, we get:\n$$ t_{1/2, \\text{mutant}} \\approx 14.4~\\mathrm{h} $$\n\n**Part 3: Qualitative justification of phenotypic consequences**\n\nAt steady state, the rate of protein synthesis, $S$, is equal to the rate of protein degradation. The rate of degradation for a protein following first-order kinetics is the product of its degradation rate constant, $k_{\\deg}$, and its steady-state abundance, $P_{\\text{ss}}$.\n$$ S = k_{\\deg} \\times P_{\\text{ss}} $$\nSolving for the steady-state abundance gives:\n$$ P_{\\text{ss}} = \\frac{S}{k_{\\deg}} $$\nThe problem states that the synthesis rate $S$ is unchanged for the mutant. We have calculated that the mutant's degradation rate constant is lower than the wild-type's: $k_{\\deg, \\text{mutant}} < k_{\\deg, \\text{WT}}$ ($0.048~\\mathrm{h}^{-1}$ vs $0.12~\\mathrm{h}^{-1}$).\nSince $P_{\\text{ss}}$ is inversely proportional to $k_{\\deg}$, a decrease in the degradation rate constant will lead to an increase in the steady-state abundance of the protein. Specifically, the ratio of mutant to wild-type steady-state levels is:\n$$ \\frac{P_{\\text{ss, mutant}}}{P_{\\text{ss, WT}}} = \\frac{S/k_{\\deg, \\text{mutant}}}{S/k_{\\deg, \\text{WT}}} = \\frac{k_{\\deg, \\text{WT}}}{k_{\\deg, \\text{mutant}}} = \\frac{0.12}{0.048} = 2.5 $$\nThe mutant transcription factor will accumulate to a steady-state level $2.5$ times higher than the wild-type protein.\nThe protein is described as a \"dosage-sensitive transcription factor that controls cell-cycle entry.\" The term \"dosage-sensitive\" implies that the cellular phenotype is sensitive to the precise amount of this protein. An overabundance of a positive regulator of cell-cycle entry would be expected to promote progression through the cell cycle. Therefore, the significant increase in the steady-state level of this transcription factor is likely to cause aberrant or uncontrolled cell proliferation. Phenotypically, this could manifest as tissue overgrowth (hyperplasia) and may predispose the individual to cancer, as uncontrolled cell-cycle entry is a hallmark of cancer. The degron-disrupting mutation effectively acts as a gain-of-function mutation by stabilizing a protein that promotes cell division.",
            "answer": "$$\\boxed{14.4}$$"
        },
        {
            "introduction": "In reality, a single protein can be subject to many different types of reversible PTMs, creating a complex combinatorial code. This problem introduces a powerful approach from systems biology to model such complexity under the assumption of independent modification events. By constructing a simple Markov model, you will calculate the steady-state probabilities for a protein to exist in different modified states, providing a quantitative foundation for understanding how cells manage and interpret these intricate PTM patterns .",
            "id": "5075808",
            "problem": "A single protein species in a human cell can experience two independent post-translational modifications: phosphorylation and ubiquitination. Each modification is reversible and occurs stochastically due to enzyme-mediated reactions. Assume the following foundational facts:\n- Post-translational modifications are chemical state changes that do not alter the amino acid sequence but change the protein’s modification state.\n- In a well-mixed environment with large numbers of enzymes and substrates, the timing of these modification events can be modeled as memoryless transitions with constant rates.\n- A Continuous-Time Markov Chain (CTMC) is appropriate for modeling such memoryless transitions between discrete states, and a steady state is reached when probability flows into each state balance the flows out.\n\nDefine the protein’s four modification states by whether it is phosphorylated ($\\mathrm{P}$) and/or ubiquitinated ($\\mathrm{U}$):\n- $S_{0}$: neither phosphorylation nor ubiquitination (none),\n- $S_{\\mathrm{P}}$: phosphorylated only,\n- $S_{\\mathrm{U}}$: ubiquitinated only,\n- $S_{\\mathrm{PU}}$: both phosphorylated and ubiquitinated.\n\nAssume that phosphorylation and ubiquitination act independently with no crosstalk: the phosphorylation addition and removal rates do not depend on whether ubiquitin is present, and vice versa. Let the phosphorylation addition and removal rates be $k_{\\mathrm{P,add}}$ and $k_{\\mathrm{P,rem}}$, and the ubiquitination addition and removal rates be $k_{\\mathrm{U,add}}$ and $k_{\\mathrm{U,rem}}$. Transitions occur only by adding or removing one modification at a time with the corresponding rate if that modification is absent or present, respectively.\n\nUse the following specific rate constants (in $\\mathrm{s}^{-1}$):\n- $k_{\\mathrm{P,add}} = 0.07$, $k_{\\mathrm{P,rem}} = 0.03$,\n- $k_{\\mathrm{U,add}} = 0.045$, $k_{\\mathrm{U,rem}} = 0.055$.\n\nConstruct the four-state CTMC implied by these rules and compute the steady-state probability of each state in the ordered basis $(S_{0}, S_{\\mathrm{P}}, S_{\\mathrm{U}}, S_{\\mathrm{PU}})$. Express your final answer as a row vector $[p(S_{0}), p(S_{\\mathrm{P}}), p(S_{\\mathrm{U}}), p(S_{\\mathrm{PU}})]$, where each entry is rounded to four significant figures. The probabilities are unitless. Do not include units in your final answer.",
            "solution": "The problem first requires validation of its premises.\n\n### Step 1: Extract Givens\n- **System**: A single protein species undergoing two independent, reversible, stochastic post-translational modifications: phosphorylation and ubiquitination.\n- **Model**: A Continuous-Time Markov Chain (CTMC) is specified for modeling the transitions between modification states, assuming memoryless transitions with constant rates. A steady state is reached when probability flows into and out of each state are balanced.\n- **States**: The four discrete states are defined by the presence or absence of phosphorylation ($\\mathrm{P}$) and ubiquitination ($\\mathrm{U}$):\n    - $S_{0}$: neither modification.\n    - $S_{\\mathrm{P}}$: phosphorylated only.\n    - $S_{\\mathrm{U}}$: ubiquitinated only.\n    - $S_{\\mathrm{PU}}$: both phosphorylated and ubiquitinated.\n- **Independence Assumption**: Phosphorylation and ubiquitination are independent processes. The rate of adding or removing one modification does not depend on the status of the other modification.\n- **Transition Rates**: The rates of modification addition and removal are given as:\n    - $k_{\\mathrm{P,add}}$: phosphorylation addition rate.\n    - $k_{\\mathrm{P,rem}}$: phosphorylation removal rate.\n    - $k_{\\mathrm{U,add}}$: ubiquitination addition rate.\n    - $k_{\\mathrm{U,rem}}$: ubiquitination removal rate.\n- **Specific Rate Constants**: The numerical values for the rates are provided in units of $\\mathrm{s}^{-1}$:\n    - $k_{\\mathrm{P,add}} = 0.07$\n    - $k_{\\mathrm{P,rem}} = 0.03$\n    - $k_{\\mathrm{U,add}} = 0.045$\n    - $k_{\\mathrm{U,rem}} = 0.055$\n- **Task**: To construct the four-state CTMC and compute the steady-state probability of each state in the order $(S_{0}, S_{\\mathrm{P}}, S_{\\mathrm{U}}, S_{\\mathrm{PU}})$, with results rounded to four significant figures.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is scientifically grounded, well-posed, and objective.\n- **Scientific Grounding**: The concept of post-translational modifications and their stochastic nature is central to molecular and cell biology. Modeling these dynamics using CTMCs is a standard and robust approach in quantitative systems biology.\n- **Well-Posedness**: The problem describes an irreducible (strongly connected), finite-state CTMC. Any state is reachable from any other state. This mathematical structure guarantees the existence of a unique, stable steady-state probability distribution.\n- **Objectivity & Completeness**: The problem is stated in precise, quantitative terms. All necessary information (states, transitions, rates, and the independence assumption) is provided, and there are no internal contradictions.\n\n### Step 3: Verdict and Action\nThe problem is valid. A complete solution will be derived.\n\n### Solution Derivation\nThe problem describes a system with four states. The transitions between these states constitute a CTMC. A direct approach would involve writing the master equation for the four state probabilities $p(S_0)$, $p(S_P)$, $p(S_U)$, and $p(S_{PU})$ and solving the resulting system of linear equations. However, the problem explicitly states that the two modification processes—phosphorylation and ubiquitination—are independent. This crucial property allows for a significant simplification by decomposing the four-state system into two independent two-state systems.\n\nFirst, let us analyze the phosphorylation dynamics in isolation. A protein can be either unphosphorylated ($\\neg P$) or phosphorylated ($P$). The transitions can be represented as a two-state Markov process:\n$$ \\neg P \\underset{k_{\\mathrm{P,rem}}}{\\stackrel{k_{\\mathrm{P,add}}}{\\rightleftharpoons}} P $$\nAt steady state, the flow of probability from $\\neg P$ to $P$ must equal the flow from $P$ to $\\neg P$. Let $\\pi_P$ be the steady-state probability of the protein being phosphorylated and $\\pi_{\\neg P}$ be the probability of it being unphosphorylated. The balance equation is:\n$$ \\pi_{\\neg P} \\cdot k_{\\mathrm{P,add}} = \\pi_P \\cdot k_{\\mathrm{P,rem}} $$\nThe probabilities must also sum to $1$:\n$$ \\pi_P + \\pi_{\\neg P} = 1 $$\nSubstituting $\\pi_{\\neg P} = 1 - \\pi_P$ into the balance equation:\n$$ (1 - \\pi_P) k_{\\mathrm{P,add}} = \\pi_P k_{\\mathrm{P,rem}} $$\n$$ k_{\\mathrm{P,add}} - \\pi_P k_{\\mathrm{P,add}} = \\pi_P k_{\\mathrm{P,rem}} $$\n$$ k_{\\mathrm{P,add}} = \\pi_P (k_{\\mathrm{P,add}} + k_{\\mathrm{P,rem}}) $$\nSolving for $\\pi_P$, we get:\n$$ \\pi_P = \\frac{k_{\\mathrm{P,add}}}{k_{\\mathrm{P,add}} + k_{\\mathrm{P,rem}}} $$\nSubsequently, the probability of being unphosphorylated is:\n$$ \\pi_{\\neg P} = 1 - \\pi_P = \\frac{k_{\\mathrm{P,rem}}}{k_{\\mathrm{P,add}} + k_{\\mathrm{P,rem}}} $$\n\nBy an identical line of reasoning, we analyze the ubiquitination dynamics. A protein can be either unubiquitinated ($\\neg U$) or ubiquitinated ($U$):\n$$ \\neg U \\underset{k_{\\mathrm{U,rem}}}{\\stackrel{k_{\\mathrm{U,add}}}{\\rightleftharpoons}} U $$\nLet $\\pi_U$ and $\\pi_{\\neg U}$ be the steady-state probabilities of being ubiquitinated and unubiquitinated, respectively. The results are analogous:\n$$ \\pi_U = \\frac{k_{\\mathrm{U,add}}}{k_{\\mathrm{U,add}} + k_{\\mathrm{U,rem}}} $$\n$$ \\pi_{\\neg U} = \\frac{k_{\\mathrm{U,rem}}}{k_{\\mathrm{U,add}} + k_{\\mathrm{U,rem}}} $$\n\nSince the two modification processes are independent, the probability of the system being in a particular combined state is the product of the probabilities of the individual, constituent states. We can now compute the steady-state probabilities for the four states of the original problem:\n- $p(S_0)$: Probability of being unphosphorylated AND unubiquitinated.\n$$ p(S_0) = \\pi_{\\neg P} \\cdot \\pi_{\\neg U} $$\n- $p(S_P)$: Probability of being phosphorylated AND unubiquitinated.\n$$ p(S_P) = \\pi_P \\cdot \\pi_{\\neg U} $$\n- $p(S_U)$: Probability of being unphosphorylated AND ubiquitinated.\n$$ p(S_U) = \\pi_{\\neg P} \\cdot \\pi_U $$\n- $p(S_{PU})$: Probability of being phosphorylated AND ubiquitinated.\n$$ p(S_{PU}) = \\pi_P \\cdot \\pi_U $$\n\nWe now substitute the given numerical values for the rate constants.\n$k_{\\mathrm{P,add}} = 0.07$, $k_{\\mathrm{P,rem}} = 0.03$\n$k_{\\mathrm{U,add}} = 0.045$, $k_{\\mathrm{U,rem}} = 0.055$\n\nFor the phosphorylation process:\n$$ \\pi_P = \\frac{0.07}{0.07 + 0.03} = \\frac{0.07}{0.10} = 0.7 $$\n$$ \\pi_{\\neg P} = 1 - 0.7 = 0.3 $$\n\nFor the ubiquitination process:\n$$ \\pi_U = \\frac{0.045}{0.045 + 0.055} = \\frac{0.045}{0.100} = 0.45 $$\n$$ \\pi_{\\neg U} = 1 - 0.45 = 0.55 $$\n\nNow, we compute the probabilities for the four combined states:\n$$ p(S_0) = \\pi_{\\neg P} \\cdot \\pi_{\\neg U} = 0.3 \\times 0.55 = 0.165 $$\n$$ p(S_P) = \\pi_P \\cdot \\pi_{\\neg U} = 0.7 \\times 0.55 = 0.385 $$\n$$ p(S_U) = \\pi_{\\neg P} \\cdot \\pi_U = 0.3 \\times 0.45 = 0.135 $$\n$$ p(S_{PU}) = \\pi_P \\cdot \\pi_U = 0.7 \\times 0.45 = 0.315 $$\n\nAs a final verification, the sum of probabilities must equal $1$:\n$$ 0.165 + 0.385 + 0.135 + 0.315 = 1.000 $$\nThe probabilities sum to $1$, confirming the consistency of the result. The problem requires the probabilities to be expressed in a row vector, rounded to four significant figures.\n\n$p(S_0) = 0.1650$\n$p(S_P) = 0.3850$\n$p(S_U) = 0.1350$\n$p(S_{PU}) = 0.3150$\n\nThe final answer is the row vector $[0.1650, 0.3850, 0.1350, 0.3150]$.",
            "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n0.1650 & 0.3850 & 0.1350 & 0.3150\n\\end{pmatrix}\n}\n$$"
        }
    ]
}